DERL3 and lung adenocarcinoma: Higher levels of Derlin‐3 protein were detected in human patient lung adenocarcinoma tissues compared to adjacent tissues, and patients with higher levels of Derlin‐3 also responded poorly to chemo and immunotherapies, suggesting upregulation of Derlin‐3 may be a potential indicator for poor sensitivity to therapeutics (Lin et al. 2022).